MedTrace Logo

Effect of BIA 5-1058 on the Steady State Pharmacokinetics of Treprostinil

NCT04675944 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-12-19

No results posted yet for this study

Summary

The purpose of this study is to assess the effect of BIA 5-1058 200 mg on the pharmacokinetic (PK) of treprostinil

Conditions

Interventions

DRUG

BIA 5-1058

200 mg (2 x 100 mg tablets), oral route

DRUG

treprostinil

1 mg (1 extended-release tablet), oral route

Sponsors & Collaborators

  • Bial - Portela C S.A.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-02-28
Primary Completion
2018-05-25
Completion
2018-05-25

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04675944 on ClinicalTrials.gov